Antisense therapy in malignant diseases: status quo and quo vadis?

Clinical Science
Ingo Tamm

Abstract

Preclinical and clinical studies indicate a role for AS ODNs (antisense oligonucleotides) as therapeutics for malignant diseases. The principle of antisense technology is the sequence-specific binding of an AS ODN to the target mRNA, resulting in a translational arrest. The specificity of hybridization makes antisense strategy attractive to selectively modulate the expression of genes involved in the pathogenesis of malignant diseases. One antisense drug has been approved for local therapy of CMV (cytomegalovirus) retinitis, and a number of AS ODNs are currently being tested in clinical trials, including AS ODN targeting Bcl-2, XIAP (X-linked inhibitor of apoptosis protein) and TGF-beta-2 (transforming growth factor beta-2). AS ODNs are well tolerated and may have therapeutic activity. In particular, an AS ODN to Bcl-2 has been tested in phase III clinical trials in chronic lymphocytic leukaemia, multiple myeloma and malignant melanoma. In this review, therapeutic concepts, clinical studies and new promising molecular targets to treat malignancies with AS ODNs are summarized.

References

Jan 1, 1978·Proceedings of the National Academy of Sciences of the United States of America·P C Zamecnik, M L Stephenson
Jan 1, 1978·Proceedings of the National Academy of Sciences of the United States of America·M L Stephenson, P C Zamecnik
Oct 1, 1977·Proceedings of the National Academy of Sciences of the United States of America·B M PatersonE L Kuff
Nov 1, 1996·Science·D J Van AntwerpI M Verma
Feb 1, 1997·Current Opinion in Genetics & Development·M E Katz, F McCormick
Apr 19, 1997·Lancet·A WebbZ Dziewanowska
Aug 1, 1997·Nature Medicine·G AmbrosiniD C Altieri
May 9, 1998·The Journal of Biological Chemistry·R TakahashiJ C Reed
Jan 23, 1999·Current Opinion in Oncology·J C Reed
Jan 23, 1999·Oncogene·E C LaCasseA E MacKenzie
Aug 7, 1999·The New England Journal of Medicine·H S SwanaD C Altieri
Nov 24, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M MonzóA Abad
Nov 24, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J P StevensonP J O'Dwyer
Dec 2, 1999·Experimental Cell Research·C Hagemann, U R Rapp
Dec 10, 1999·Nature Cell Biology·J C Reed, S I Reed
Mar 31, 2000·Trends in Pharmacological Sciences·E KollerB P Monia
Apr 28, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A M Gewirtz
Apr 28, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J S WatersF E Cotter
May 12, 2000·Biochimica Et Biophysica Acta·B F Baker, B P Monia
May 12, 2000·Biochimica Et Biophysica Acta·S T Crooke
May 12, 2000·Biochimica Et Biophysica Acta·J Summerton
Aug 22, 2001·Lancet·I TammG Hartmann
Oct 18, 2001·Journal of the National Cancer Institute·J R KanwarG W Krissansen
Oct 26, 2001·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·B CoudertUNKNOWN European Organization for Research and Treatment of Cancer (EORTC)
Feb 7, 2002·Journal of the American Chemical Society·Ruben DeclercqLuc Van Meervelt
Mar 22, 2002·The Lancet Oncology·I TammB Dörken
Jun 18, 2002·Nature·Helen DaviesP Andrew Futreal
Aug 7, 2002·Antisense & Nucleic Acid Drug Development·Anthony SandrasagraJonathan W Nyce
Sep 3, 2002·Advanced Drug Delivery Reviews·Irène BriggerPatrick Couvreur
Mar 18, 2003·Cellular Signalling·Huira ChongKun-Liang Guan
Aug 30, 2003·Oncogene·Usha Kasid, Anatoly Dritschilo
Mar 17, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Charles M RudinEverett E Vokes
May 12, 2004·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·Pal AukrustLars Gullestad

❮ Previous
Next ❯

Citations

Oct 17, 2006·Wiener medizinische Wochenschrift·Volker Wacheck
Oct 21, 2009·The Journal of Experimental Medicine·Domagoj Vucic, Vishva M Dixit
Nov 1, 2009·Future Medicinal Chemistry·Chudi NdubakuDomagoj Vucic
Apr 2, 2009·Expert Opinion on Investigational Drugs·Camilla StapnesØystein Bruserud
Jun 1, 2007·Expert Opinion on Drug Discovery·Irene M Lagoja, Piet Herdewijn
May 1, 2010·Drug Delivery·Victoria ElazarGershon Golomb
Aug 29, 2006·Seminars in Cancer Biology·Marina Vita, Marie Henriksson
Jun 6, 2009·Seminars in Nuclear Medicine·Mathew L Thakur
Sep 2, 2008·The Lancet Oncology·Justin A CallD Ross Camidge
Feb 23, 2007·Nature Clinical Practice. Endocrinology & Metabolism·Marinella Messina, Bruce G Robinson
Sep 9, 2017·Journal of Medical Ethics·David Shaw, Dale Gardiner

❮ Previous
Next ❯

Related Concepts

Related Feeds

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.

BCL-2 Family Proteins

BLC-2 family proteins are a group that share the same homologous BH domain. They play many different roles including pro-survival signals, mitochondria-mediated apoptosis and removal or damaged cells. They are often regulated by phosphorylation, affecting their catalytic activity. Here is the latest research on BCL-2 family proteins.

Antisense Oligonucleotides: ND

This feed focuses on antisense oligonucleotide therapies such as Inotersen, Nusinursen, and Patisiran, in neurodegenerative diseases including amyotrophic lateral sclerosis.

B-Cell Leukemia (Keystone)

B-cell leukemia includes various types of lymphoid leukemia that affect B cells. Here is the latest research on B-cell leukemia.